Tasimelteon ( DrugBank: Tasimelteon )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 202 | スミス・マギニス症候群 | 2 |
202. スミス・マギニス症候群
臨床試験数 : 10 / 薬物数 : 12 - (DrugBank : 5) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02776215 (ClinicalTrials.gov) | September 2016 | 16/5/2016 | Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | Circadian Rhythm Sleep Disorders;Non-24 Hour Sleep-Wake Disorder;Autism Spectrum Disorder;Smith-Magenis Syndrome | Drug: tasimelteon | Vanda Pharmaceuticals | NULL | Recruiting | 3 Years | 17 Years | All | 24 | Phase 1 | United States |
| 2 | NCT02231008 (ClinicalTrials.gov) | September 2015 | 29/8/2014 | Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS | Smith-Magenis Syndrome;Circadian | Drug: tasimelteon | Vanda Pharmaceuticals | NULL | Recruiting | 16 Years | 65 Years | Both | 48 | Phase 2/Phase 3 | United States |